First-in-human safety, pharmacokinetics, and preliminary efficacy of
TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET

D. Hong; L. Bazhenova; B.C. Cho; S. Sen; M. Ponz-Sarvise; R. Heist; Z. Zimmerman; X. Le; D. Xuan; Z. Junming; J. Lee

151 308

Cited 0 times in

First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET

Authors: D. Hong ; L. Bazhenova ; B.C. Cho ; S. Sen ; M. Ponz-Sarvise ; R. Heist ; Z. Zimmerman ; X. Le ; D. Xuan ; Z. Junming ; J. Lee

Citation: EUROPEAN JOURNAL OF CANCER, Vol.138 : S1, 2020-10

Journal Title: EUROPEAN JOURNAL OF CANCER

ISSN: 0959-8049

Issue Date: 2020-10

Files in This Item:: T999202168.pdf Download

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
3. College of Nursing (간호대학) > Dept. of Nursing (간호학과) > 1. Journal Papers

Yonsei Authors: Cho, Byoung Chul(조병철) https://orcid.org/0000-0002-5562-270X
Choi, Mona(최모나) https://orcid.org/0000-0003-4694-0359

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/184929

사서에게 알리기

Show full item record Find it @ YMLIB

YUHSpace: First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET

YUHSpace

BROWSE

Browse

Links